Prostate cancer
DARO-LIPID
Randomised Phase 2 study of sphingosine kinase inhibitor (opaganib) in addition to darolutamide in people with poor prognostic metastatic castration resistant prostate cancer (mCRPC) based on a companion circulating lipid biomarker, PCPro.
Trial overview
Clinical Area
Medical Oncology
Disease
Prostate
Disease site
Genitourinary (GU)
Study Phase
II
Trial Identifiers
Registration number: ACTRN12624001458527
https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12624001458527
GenesisCare Location(s)
Principal Investigator(s)